|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Departments of Pediatrics and Pharmacology (Dr. Moore and Mr. Calder), Vanderbilt University School of Medicine, Nashville, TN; Physiology Program (Drs. Silverman and Shore), Harvard School of Public Health, Boston, MA; and Department of Medicine (Dr. Panettieri), University of Pennsylvania, Philadelphia, PA.
Correspondence to: Paul E. Moore, MD, Division of Pediatric Pulmonary Medicine, Vanderbilt University School of Medicine, 1161 21st Ave South, S0119 MCN, Nashville, TN 37232-2586
We examined the ability of the corticosteroid dexamethasone to inhibit short-term (1 h) and long-term (24 h) ß2-adrenergic desensitization in cultured human airway smooth muscle (HASM) cells. In cells from 19 individuals studied on 47 experimental days, pretreatment with isoproterenol at 10-7 mol/L for 1 h or 24 h caused approximately 21% and 77% decreases in the ability of subsequent isoproterenol (10-6 mol/L) stimulation to reduce HASM cell stiffness as measured by magnetic twisting cytometry, similar to results we have previously reported.1 We examined the ability of dexamethasone (10-6 mol/L) administered 6 h or 48 h prior to isoproterenol pretreatment, and stratified our results by presence or absence of the Arg19 allele of the ß2AR upstream peptide, located in the 5'-leader cistron of the ß2AR gene. This polymorphism has been associated with decreased ß2AR expression in HASM cells. In cells containing at least one Arg19 allele, dexamethasone did not significantly reverse short-term or long-term desensitization, but in cells without the Arg19 allele, dexamethasone significantly reversed short-term and long-term desensitization (35% and 31%, respectively; p < 0.05 for each). Our results suggest that the Arg19 allele, or other polymorphisms of the promoter of the ß2AR gene that are in linkage disequilibrium, may affect the ability of dexamethasone to upregulate ß2AR expression in HASM cells. In addition, our results suggest that ß2AR genotype may be predictive of corticosteroid responsiveness in individuals with asthma.
| Footnotes |
|---|
This abstract is supported by National Institutes of Health grants HL04395, HL56383, HL33009, and HL67663, and the American Lung Association.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. L. Toews and D. B. Bylund Pharmacologic Principles for Combination Therapy Proceedings of the ATS, November 1, 2005; 2(4): 282 - 289. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |